While this supports the negative role of MARCO in the long-term following adjuvant therapy, the dynamics may differ in the short-term—in an orthogonal study of neoadjuvant PD1 therapy in GBM, MARCO was reported as one of the top increased genes in patients treated with pembrolizumab approximately 2 weeks prior to sample acquisition [51]. This evidence concerns the gene MARCO and glioblastoma.